Search for a trial

Synaptic density and tau pathology in Alzheimer's disease

This study has been transitioned to CTIS with ID 2024-517636-22-00 check the CTIS register for the current data. The main objective of the present study is to investigate the association between in vivo regional synaptic loss ([18F]SynVesT-1 PET),…

Treatment of severe gout patients with rasburicase

The primary outcome parameter is the Gout Activity Score (GAS)after 6 months of rasburicase treatment. Secondary outcome parameters are the serum uric acid concentration, the clinical evaluation of tophus load, patient reported outcomes: MD-HAQ, GAQ…

OPEN LABEL PHASE 2 BASKET TRIAL WITH ATEZOLIZUMAB AND TIRAGOLUMAB IN SOLID TUMORS: TIRACAN

This study has been transitioned to CTIS with ID 2024-512616-21-00 check the CTIS register for the current data. The main objective of the trial is to determine the pathological response rate in cohort 1 and the radiological response rates in cohort…

A Multi-Center Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Dapansutrile Tablets in Subjects with an Acute Gout Flare

This study has been transitioned to CTIS with ID 2024-518844-20-00 check the CTIS register for the current data. Primary Objective:To evaluate the efficacy of dapansutrile as an acute gout flare treatment compared to placebo in reducing joint pain…

A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer

This study has been transitioned to CTIS with ID 2024-516327-14-00 check the CTIS register for the current data. This study is evaluating the preliminary efficacy of UV1-olaparib-durvalumab combination against both olaparib as monotherapy and…

Specifying the anti-inflammatory effects of ziltivekimab with diverse imaging modalities and in-depth cellular phenotyping

This study has been transitioned to CTIS with ID 2024-515893-29-01 check the CTIS register for the current data. To study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory…

Safety, tolerability and immunogenicity of intradermal mRNA SARS-CoV2 vaccination in patients with
Fibrodysplasia Ossificans Progressiva

This study has been transitioned to CTIS with ID 2024-518686-10-00 check the CTIS register for the current data. To describe and investigate safety and tolerability of the intradermal delivery of two fractional doses of 3/3 µg Comirnaty Original/…

Phase I/II study with galunisertib combined with capecitabine in patients with advanced chemotherapy resistant colorectal cancer with peritoneal metastases

This study has been transitioned to CTIS with ID 2024-518980-37-00 check the CTIS register for the current data. With this clinical study, we aim to gain more information about the pharmacological characteristics, safety profile, tolerability and…

A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third generation EGFR TKI

This study has been transitioned to CTIS with ID 2024-512288-29-00 check the CTIS register for the current data. The aim of this prospective single-arm phase II study is to evaluate the efficacy of amivantamab and bevacizumab added to continued…

The CanISleepinMS Study:
Effect of cannabidiol (CBD) on sleep quality in patients with multiple sclerosis, a series of 15 randomised, placebo-controlled N-of-1 trials

This study has been transitioned to CTIS with ID 2024-518280-35-00 check the CTIS register for the current data. To investigate the effect of CBD on MS patients with impaired sleep quality.

A Phase 2, randomised, double-blind, placebo-controlled, 2-way crossover study to evaluate the efficacy, safety, and tolerability of NMD670 in ambulatory adults with Type 3 spinal muscular atrophy

This study has been transitioned to CTIS with ID 2024-516321-31-00 check the CTIS register for the current data. The purpose of this study is to measure clinical efficacy on muscle strength and function, safety, and tolerability of NMD670 compared…

Treatment study for children and adolescents with Acute Promyelocytic Leukemia

This study has been transitioned to CTIS with ID 2024-518669-83-00 check the CTIS register for the current data. Primary objective:To assess, in an international pediatric study, the efficacy, in terms of event-free survival, of a combination of ATO…

A Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Ampligen® Compared to Control Group / No Treatment Following FOLFIRINOX in Subjects with Locally Advanced Pancreatic Adenocarcinoma

This study has been transitioned to CTIS with ID 2024-518627-29-00 check the CTIS register for the current data. PRIMARY OBJECTIVE• To compare the efficacy of Ampligen® versus control group / no treatment following FOLFIRINOX in subjects with…

Assess effect and safety of intra-arterial autologous mesoangioblasts administration to the upper arm of m.3243A>G mutation carriers

This study has been transitioned to CTIS with ID 2024-515129-27-00 check the CTIS register for the current data. In our phase IIa trial we will determine the effect and safety of three MABs administrations in the m. biceps brachii in m.3243A>…

PROSPER: Addressing mental health problems and preventing recidivism in the criminal justice system

The primary aim of this study is to investigate the feasibility, acceptability and user-friendliness of implementing PM+ in Dutch prisons. This is a version of PM+ that is specifically adapted to the prisoner population and prison context. The…

Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

This study has been transitioned to CTIS with ID 2024-517150-10-00 check the CTIS register for the current data. Primary:- To evaluate the safety and tolerability, and define the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of…

A phase II, open label, multi-center study of 89Zr-DF-Crefmirlimab for CD8 positron emission tomography in patients with locally advanced or metastatic solid tumours

This study has been transitioned to CTIS with ID 2024-515885-15-00 check the CTIS register for the current data. Main objectives:• To evaluate whole body distribution of 89Zr-Df-crefmirlimab in cancer patients prior to and during treatment with an…

A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

This study has been transitioned to CTIS with ID 2024-514266-39-00 check the CTIS register for the current data. Phase 1 Primary Objective(s):-to evaluate the overall safety and tolerability of NVL-655-to determine the RP2D and, if applicable, the…

A Randomized Phase II Study of Systemic Chemotherapy with or without HAI FUDR/Dexamethasone in Patients with Unresectable Intrahepatic Cholangiocarcinoma

This study has been transitioned to CTIS with ID 2024-518065-10-00 check the CTIS register for the current data. The aim of the study is to demonstrate that HAI P chemotherapy is an effective treatment for unresectable intrahepatic…